EGFR and non-small cell lung carcinoma: Up to now, the European Medicines Agency (EMA) [58] and the FDA [59] have approved epidermal growth factor receptor (EGFR) mutation testing using ctDNA in non-small-cell lung cancer (NSCLC) patients.